Portage biotech announces collaboration with merck to evaluate two next-generation adenosine antagonists in combination with keytruda® (pembrolizumab) in solid tumors

Westport, conn., sept. 05, 2023 (globe newswire) -- portage biotech inc. (nasdaq: prtg), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today announced that it has entered into a clinical trial collaboration agreement with merck (known as msd outside the us and canada) to evaluate portage's next-generation adenosine antagonists in combination with keytruda® (pembrolizumab), merck's anti-pd-1 (programmed death receptor-1) therapy, for patients with solid tumors. the collaboration will explore portage's adenosine 2a receptor (a2ar) antagonist, port-6, its adenosine 2b receptor (a2br) antagonist, port-7, individually and together in combination with keytruda in prostate, renal, head and neck, colorectal, endometrial, ovarian and non-small cell lung cancers.
ATON Ratings Summary
ATON Quant Ranking